The authors note that Fig. 3 appeared incorrectly. Panel B (Top) depicting the time course of NF-κB activation in wild type and caspase-1 deficient peritoneal macrophages is not the same version as the authors submitted originally to PNAS. A correct version including vertical rules to indicate splicing is shown below. Regarding panel C, during the preparation of the manuscript, we inadvertently repeated a set of p38 blots corresponding to p-p38 Western blots. The correct p38 Western blots are shown below. The findings of the paper have not been affected by the error and the authors apologize to the editors and readers. The corrected figure and its legend appear below. . Caspase-1 is required for Mal to signal. (A) (Upper) U373 cells were transfected with a 5x NF-κB reporter gene plasmid. Cells were left untreated or pretreated with YVAD-Cmk (100 μM) or IL-1 receptor antagonist (1 μg/ml) for 1 h. Thereafter, cells were untreated or incubated with LPS (1 μg/ml) or IL-1 (100 ng/ml) for 6 h. Shown is the mean relative stimulation of luciferase activity ± SD for a representative experiment from three separate experiments. (Lower) THP-1 cells were left untreated or pretreated with YVAD-Cmk (100 μM) or IETD-Fmk (50 μM) for 1 h followed by treatment with Pam 3 Cys (1 μg/ml) or IL-1 (1 μg/ml) for 0-120 min. Activation of p38 was analyzed by using an anti-phospho-p38-specific antibody. (B) (Top) Time course of NF-κB activation in wild-type and caspase-1-deficient peritoneal macrophages stimulated with LPS (10 ng/ml), Malp-2 (10 nM), and R848 (10 μM) as detected by EMSA. (Middle) Supershift assay was performed by using an anti-p65 antibody for 1 h before analysis by EMSA. Protein:DNA complexes are shown. (Bottom) Wild-type and caspase-1-deficient murine embryonic fibroblasts were treated with LPS (100 ng/ml), lipid A (100 ng/ml), or Malp-2 (10 nM) as indicated, followed by immunoblot analysis of the cell lysates with antibodies directed against IκBα or β-actin. (C) Time course of p38 activation in wild-type and caspase-1-deficient peritoneal macrophages stimulated with LPS (100 ng/ml), Malp-2 (10 nM), and IL-1 (1 μg/ml) analyzed by immunoblotting with phospho-p38-specific antibodies. Total p38 levels are also shown. (D) Time course of p38 activation in wild-type and caspase-1-deficient peritoneal murine embryonic fibroblasts stimulated with LPS (100 ng/ml) or Malp-2 analyzed by immunoblotting with phospho-p38-specific antibodies. Total p38 levels are also shown.
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Caspase-1 plays a key role in inflammatory responses by cleaving pro-IL-1␤, pro-IL-18, and probably pro-IL-33 into their bioactive forms (6, 7) . Caspase-1 occurs in multiprotein complexes called inflammasomes (8) , three of which have been characterized to date (9) . One of these inflammasomes comprises the Nod-like receptor (NLR) protein Nalp1 in a complex with caspase-1, caspase-5, and the adapter protein apoptosis-associated speck-like protein (ASC) (10) . The second inflammasome contains two other NLRs, Nalp3 and Nalp2, along with caspase-1, ASC, and Cardinal (10). The Nalp3-containing inflammasome is activated by bacterial RNA, certain bacterial toxins and ATP, and uric acid crystals (9, 11, 12) . The third inflammasome contains another NLR termed Ipaf, and caspase-1 is activated by bacterial flagellin (13, 14) . ASC has a particularly important role in caspase-1 activation because ASCdeficient macrophages are unable to activate caspase-1 in response to a number of stimuli (15) . In all cases so far, TLR ligands are required to prime inflammasomes for activation, although the mechanism is not known.
In an effort to discover proteins that interact with Mal, we carried out a yeast two-hybrid screen and identified caspase-1 as a Malinteracting protein. Further, signaling by TLR2 and TLR4, but not TLR7 or IL-1, is impaired in caspase-1-deficient cells, and cleavage of Mal by caspase-1 is required for Mal to signal. We have therefore revealed an additional function for caspase-1 in the regulation of TLR2 and TLR4 signaling and provided an important functional link between TLRs and NLRs in inflammasomes.
Results
Mal Interacts with Caspase-1. By using a yeast two-hybrid-based screening assay with full-length Mal as a bait and a target splenocyte cDNA library, we identified a total of 20 Mal-positive unique interacting clones. The most interesting encoded a portion of caspase-1 spanning the p20 and p10 subunits, which, in the active enzyme, comprise the catalytic domain. When tested in a bait/ interactor format, Mal was shown to interact with caspase-1 ( Mal Is Not Required for Caspase-1 Activation. We next analyzed the production of mature IL-1␤ in Mal-deficient macrophages in response to TLR ligands. Fig. 2A Left shows that wild-type macrophages produced IL-1␤ in response to LPS, the TLR2 ligand Malp-2, and the TLR7/8 ligand R848. None of the ligands induced IL-1␤ in MyD88-deficient cells, and the LPS and Malp-2 response was abolished in TLR4-and TLR2-deficient cells, respectively. IL-1␤ production was also significantly impaired in Mal-deficient macrophages treated with LPS or Malp2, as shown by an ELISA on cell supernatants ( Fig. 2 A Left) and upon Western blotting of pro-IL-1␤ whole-cell lysates (Right), the latter also being the case in MyD88-deficient cells (data not shown). The inability of LPS and Malp-2 to induce IL-1␤ production in Mal-deficient macrophages is therefore likely to be due to effects on expression rather than processing. We next tested more directly whether Mal was required for caspase-1 activation by examining caspase-1 processing. The processed p10 subunit of caspase-1 could be detected in bone marrow-derived and peritoneal macrophages (data not shown) from both wild-type (Fig. 2B, lane 4) and Mal-deficient (Fig. 2B , lane 8) mice.
TLR2 and TLR4 Signaling Is Impaired in Caspase-1-Deficient Cells. We next tested whether caspase-1 was required for Mal to signal. As shown in Fig. 3A , preincubation of cells with the caspase-1 inhibitor YVAD-Cmk blocked the activation of NF-B by LPS. This blockage was unlikely a result of IL-1 mediating the effect of these stimuli because pretreatment with the IL-1 receptor antagonist had no effect. The cells are also unresponsive to IL-18. As also shown in Fig. 3A , the inhibition did not block the effect of IL-1 on NF-B. We also examined p38 MAP kinase activation. We tested Pam 3 Cys here because unlike LPS, it only uses the adapters MyD88 and Mal (4, 16, 17) . Pretreatment of THP-1 cells with the caspase-1 inhibitor blocked the early phase activation of p38 MAP kinase (Fig. 3A Lower, compare top panel with middle panel), whereas a caspase-8 inhibitor was without effect (Fig. 3A Lower) . The caspase-1 inhibitor did not affect IL-1-mediated activation of p38 MAP kinase (Fig. 3A Lower, compare upper and lower panels on the right side of the figure). Moreover, LPS and Malp-2 stimulated caspase-1- deficient peritoneal macrophages displayed an impairment in NF-B activation when compared with the TLR 7/8 ligand R848, as judged in an EMSA (Fig. 3B , top three panels) or by measuring IB degradation (Fig. 3B, bottom three blots) . Similarly, p38 MAP kinase activation was impaired in caspase-1-deficient macrophages and murine embryonic fibroblasts treated with LPS or Malp2 (Fig.  3 C and D) but not IL-1 (Fig. 3C) . In addition, TNF-␣ levels were reduced in caspase-1-deficient macrophages treated with LPS and Pam 3 Cys (Table 1) , whereas TNF-␣ levels were normal after stimulation with R848. Complete impairment of TNF-␣ production was not evident in caspase-1-deficient cells because noncleaved Mal may still retain its structural role as a bridging adaptor between TLR2/4 and MyD88, thereby facilitating impaired signaling through MyD88. These data indicate a role for caspase-1 in TLR-2 and TLR-4 signaling but not in TLR 7/8 or IL-1 signaling, the difference between these sets of receptors being Mal utilization. Fig. 4B Bottom, lane 4) . Examination of endogenous Mal in THP-1 cells showed it to be cleaved after 15-min treatment of cells with either LPS (Fig. 4C Left) or Lipid A (Fig. 4C Right) . Mal cleavage correlated with the appearance of the p10 subunit of caspase-1 in the cell lysates (Fig. 4C Left Lower) , indicative of concomitant caspase-1 activation. Mal cleavage was blocked by a caspase-1 inhibitor (Fig. 4C Right, lane 3) . THP-1 cells display caspase-1 activation in response to LPS alone and thus do not require costimulation with ATP (19, 20) . In mouse macrophages, treatment with LPS led to the appearance of an additional form of Mal that was 2.5 kDa smaller in molecular mass than the major form of Mal (Fig. 4D Left) , consistent with cleavage of murine Mal by caspase-1 at the putative caspase-1 cleavage site, and Mal was unaffected in LPS-treated caspase-1-deficient macrophages (Fig. 4D Right) . These data therefore demonstrate that Mal is cleaved by caspase-1.
Intact Mal Does Not Activate NF-B.
We next carried out experiments on Mal-D198A, which cannot be degraded by caspase-1. Mal-D198A can still interact with caspase-1 (Fig. 4E, lane 4) , but as shown in Fig. 4B , it is not a substrate. Whereas Mal overexpression activated NF-B, Mal-D198A was inactive (Fig. 4F) . Mal-D198A acted as a dominant-negative inhibitor toward both LPS and Pam 3 Cys stimuli (Fig. 4F ) but had no effect on TNF-␣ signaling (Fig. 4F) . Using an IL-8 promoter-dependent reporter gene, we Fig. 3 . Caspase-1 is required for Mal to signal. (A) (Upper) U373 cells were transfected with a 5x NF-B reporter gene plasmid. Cells were left untreated or pretreated with YVAD-Cmk (100 M) or IL-1 receptor antagonist (1 g/ml) for 1 h. Thereafter, cells were untreated or incubated with LPS (1 g/ml) or IL-1 (100 ng/ml) for 6 h. Shown is the mean relative stimulation of luciferase activity Ϯ SD for a representative experiment from three separate experiments. (Lower) THP-1 cells were left untreated or pretreated with YVAD-Cmk (100 M) or IETD-Fmk (50 M) for 1 h followed by treatment with Pam 3Cys (1 g/ml) or IL-1 (1 g/ml) for 0 -120 min. Activation of p38 was analyzed using an anti-phospho-p38-specific antibody. (B) (Top) Time course of NF-B activation in wildtype and caspase-1-deficient peritoneal macrophages stimulated with LPS (10 ng/ml), Malp-2 (10 nM), and R848 (10 M) as detected by EMSA. (Middle) Supershift assay was performed by using an anti-p65 antibody for 1 h before analysis by EMSA. Protein:DNA complexes are shown. (Bottom) Wild-type and caspase-1-deficient murine embryonic fibroblast were treated with LPS (100 ng/ml), lipid A (100 ng/ml), or Malp-2 (10 nM) as indicated, followed by immunoblot analysis of the cell lysates with antibodies directed against IB␣ or ␤-actin. (C) Time course of p38 activation in wild-type and caspase-1-deficient peritoneal macrophages stimulated with LPS (100 ng/ml), Malp-2 (10 nM), and IL-1 (1 g/ml) analyzed by immunoblotting with phospho-p38-specific antibodies. Total p38 levels are also shown. (D) Time course of p38 activation in wild-type and caspase-1-deficient peritoneal murine embryonic fibroblasts stimulated with LPS (100 ng/ml) or Malp-2 analyzed by immunoblotting with phospho-p38-specific antibodies. Total p38 levels are also shown. Wild-type or caspase-1-deficient peritoneal macrophages (0.5 ϫ 10 6 /well) were treated with LPS (10 ng/ml), Pam 3Cys (100 ng/ml), or R848 (10 M) for 16 h. Cytokine production was then assessed by ELISA. Results shown are mean Ϯ SD. A similar result was obtained in another independent experiment.
show that Mal-D198A does not induce this promoter and that induction of the IL-8 promoter by Pam 3 Cys was blocked by Mal-D198A (Fig. 4G) , whereas Mal-D198A did not affect induction by IL-1 (Fig. 4G) . Moreover, HEK293 cells contain ASC, a component of TLR-mediated caspase-1 activity (15) (Fig. 4F) , and caspase-1 is activated by treatment of these cells with LPS (Fig. 4F,  lane 5) . The mutant Mal was therefore inactive most likely because it was not cleaved by caspase-1. Taken together, our data therefore strongly suggest that cleavage of Mal by caspase-1 is required for Mal to mediate NF-B activation.
Discussion
Our study provides a clear, specific aspect to Mal that distinguishes it from the other adapters in TLR signaling (4, 5, 21, 22) , in that it is cleaved by caspase-1. Whereas Mal was not required for caspase-1 activation, caspase-1 appeared to be required for the ability of Mal to activate NF-B. TLR2 and TLR4 signaling was blocked by a caspase-1 inhibitor and was attenuated in caspase-1-deficient macrophages and murine embryonic fibroblasts. All responses tested were affected. Moreover, IL-1 and TLR7 signaling remained normal in these cells. Because the only known difference for these signals between TLR2 and TLR4 on the one hand and IL-1RI and TLR7 on the other is a role for Mal, this result provides circumstantial evidence that caspase-1 was targeting Mal for activation. We then demonstrated that Mal is a substrate for caspase-1 and that a mutant form of Mal, which cannot be cleaved, was unable to activate NF-B. Finally, we demonstrated that this mutant form of Mal could still interact with caspase-1 but when overexpressed acted as a dominant negative inhibitor of TLR2 and TLR4 signaling. We were therefore able to conclude that Mal is a substrate for caspase-1 and must undergo cleavage to be active. The effect of caspase-1 on Mal is unique among the TIR adapters. We found that MyD88 was not a substrate, and Trif and Tram are unlikely to be regulated by caspase-1 because similar to MyD88 they lack a caspase-1 cleavage site in their primary structures. We have therefore revealed a mechanism for Mal activation and a function for caspase-1 in the regulation of TLR2 and TLR4 signaling.
The first question that arises is how caspase-1 might be activated during TLR2 and TLR4 activation to allow for Mal processing. Caspase-1 has been shown to occur in different protein complexes termed inflammasomes (8) , of which three have been described to date (9) . How caspase-1 is activated in these inflammasomes is poorly understood, but in all cases TLR ligands such as LPS appear to be required for priming of the inflammasome for subsequent activation by agents such as ATP (15, 23) . There is, however, disagreement in the literature concerning this priming event and whether TLR activation alone is sufficient to activate caspase-1. A recent study has shown that ultrapure LPS alone can activate caspase-1 in murine macrophages (11) or in certain cell lines such as THP-1 (8) . It is possible that the issue here is magnitude; TLR stimulation alone will activate caspase-1, but this response requires amplification by endogenous factors such as uric acid or ATP, which acts via Nalp3 (16) . Given that Mal requires cleavage by caspase-1 to be active, it is therefore possible that during infection, bacterial products will be sensed by TLRs but will also lead to the activation of caspase-1 in inflammasomes, an effect amplified by the generation of endogenous ligands. Caspase-1 will then process Mal into its active form, amplifying signaling by TLR2 and TLR4.
Regarding the TLR adapters, caspase-1 activation by LPS has been shown to be normal in MyD88-, Trif- (24), and, from our study, Mal-deficient macrophages. The caspase-1 assay relies on cells primed with LPS or Pam 3 Cys and then treated with ATP (15) . The response measured is the appearance of the p10 or p20 subunits of caspase-1, which are indicative of autoprocessing. We cannot fully rule out a role for Mal in caspase-1 function, however, because the precise role of caspase-1 processing for its activity is uncertain. Although caspase-1 activation was unaffected in Mal-deficient cells, we found that the production of IL-1␤ and IL-18 was impaired, identifying these cytokines as being on the MyD88/Mal-dependent pathway. This effect was due to Mal having a role in the induction of pro-IL-1␤.
Our results also provide a previously unsuspected function for caspase-1 activity. Pro-IL-1␤, pro-IL-18, and possibly pro-IL-33 are the only previously described physiological substrates for caspase-1 (6, 18, 25) . We can now add Mal to this list. Our findings may explain the profound phenotype of caspase-1-deficient mice, which, unlike IL-1␤ and IL-18 knockout (KO) mice, and as recently shown in IL-1␤/IL-18 double KO mice (26) , are completely resistant to the effects of LPS (27) (28) (29) and are also highly susceptible to infection with pathogens such as Escherichia coli (30, 31) . Similar to our study, others have shown defects in LPS responses in caspase-1-deficient macrophages such as induction of TNF, IL-6, and IL-1␣ (20, 29, 31) . TNF production in response to LPS was not affected by a neutralizing antibody to IL-18 or in IL-1␤-deficient mice (32, 33) . Our data however provide an explanation because the defect in TLR4 signaling in caspase-1-deficient mice is likely to be because Mal is not cleaved. Similar to our study, two other recent studies have found proteins that interact with caspase-1. Chae et al. (34) have shown that the protein Pyrin interacts directly with caspase-1 and interferes with its activation. Sarkar et al. (20) have shown that Receptor Interacting Protein-2 (RIP2) interacts with caspase-1 and that this interaction is somehow required for NF-B activation, although direct evidence for this effect was not provided. Similar to our data, NF-B activation by LPS was attenuated in caspase-1-deficient macrophages and was inhibited by a catalytically inactive form of caspase-1. This effect was interpreted as being due to impairment in RIP2 activation. Our results provide an additional explanation because this response may be due to the lack of Mal cleavage in caspase-1-deficient cells and somehow RIP2 may also be required for this process. An important outstanding question concerns the reason why Mal is cleaved by caspase-1. It is possible that an inhibitory domain is released from Mal. Alternatively, an active moiety from Mal is released. These possibilities should be examined. Ultimately, Mal is fully degraded in a SOCS-1-dependent manner (35) .
In conclusion, our findings demonstrate a role for caspase-1 in inflammation beyond its ability to process pro-IL-18 or pro-IL-1␤, implicating it in the regulation of many proinflammatory genes. Thus, Mal has a specific property among the TLR adapter proteins in that it requires cleavage by caspase-1 to elicit the downstream signal NF-B. These findings therefore reveal an important mechanism for the coordinated activation of host defense responses by TLRs and NLR-containing inflammasomes (9) .
Materials and Methods
Biological Reagents and Cell Culture. Thioglycollate was from REMEL Inc. (Lenexa, KS). Highly purified protein-free LPS derived from E. coli strain 011:B4 was used in all treatments. Synthetic Malp-2 was from the EMC Microcollection (Tuebingen, Germany). Pam 3 Cys, human recombinant caspase-1 and caspase-8, YVAD-Cmk, IETD-Fmk, Mal inhibitor, and control peptides were from Calbiochem (San Diego, CA). pcDNA3.1-caspase-1-AU1 was a gift from Seamus Martin (Trinity College, Dublin). Antibodies to caspase-1 (A-19) and p10 subunit (M-20) were from Santa Cruz Biotechnology (Santa Cruz, CA). Rabbit anti-Mal antibody was raised against full-length human Mal (Clone R4; Trinity College, Dublin).
Sources of Macrophages.
Mal/TIRAP KO, MyD88 KO, TLR4 KO, and TLR2 KO mice were constructed as described (4, 36, 37) . MyD88 KO mice were backbred to C57BL/6 for 15 generations, and Mal/TIRAP KO mice were on a mixed C57BL/6 and 129 background. Caspase-1 KO and wild-type mice were supplied by W. Wong (BASF Bioresearch Corporation, Worcester, MA). All mice were confirmed as being homozygous mutants by PCR genotyping of DNA. All of the animal protocols used in this study were approved by the Institutional Animal Care and Use Committee at the University of Massachusetts Medical School (Worcester, MA) and in accordance with Animals (Scientific Procedures) Act of 1986, United Kingdom.
Yeast Two-Hybrid Analysis. Full-length Mal, TIR domain of Mal, N-terminal domain of Mal, and full-length MyD88 were subcloned into pGBKT7 downstream of the Gal4 DNA-binding domain. pGBKT7:full-length Mal was used as a bait to screen a cDNA library prepared from human splenocytes expressed in the yeast strain AH109 essentially as described by the manufacturer (Matchmaker Gal4 Two-Hybrid System 3; Clontech, Palo Alto, CA). The combinations tested on His-Leu-Trp-Ade indicate protein-protein interactions.
Reporter Assays. HEK293, HEK293-TLR-4, HEK293-TLR2, and U373 cells (2 ϫ 10 4 cells per well; 96-well plate) were transfected with 80 ng per well 5x NF-B luciferase reporter gene plasmid and cotransfected with the expression vectors pcDNA3:Mal or pcDNA3:Mal-D198A by using GeneJuice essentially as described by the manufacturer (Novagen, Madison, WI). In all cases, 40 ng per well of phRL-TK reporter gene was cotransfected to normalize data for transfection efficiency. HEK293, HEK293-TLR2, and HEK293-R1 cells (2 ϫ 10 4 cells per well; 96-well plate) were transfected with the 80 ng per well IL-8 promoter reporter plasmid (38) and cotransfected with the expression vectors pcDNA3:Mal-HA or pcDNA3:Mal-D198A-HA by using Gene-
